Is Pfizer's COVID Vaccine Growth Story Already Over?

No matter how you look at it, Pfizer (NYSE: PFE) has had a remarkable year in 2020. The big drugmaker made a critical decision early on to team up with German biotech BioNTech (NASDAQ: BNTX) on developing a COVID-19 vaccine. That decision has paid off, with Pfizer and BioNTech becoming the first coronavirus-vaccine makers to win emergency use authorization (EUA) in the U.S.

Pfizer stock generated double-digit percentage gains over the last month as investors' enthusiasm about its coronavirus vaccine rose. However, those gains have now all but evaporated. Is Pfizer's COVID vaccine growth story already over?

Image source: Getty Images.

Continue reading

Source Fool.com